1629658-28-1

Basic information

• Product Name: C₁₄H₁₇ClFNO₄
• CAS NO: 1629658-28-1
• Molecular Weight: 317.745
• Mol File: 1629658-28-1.mol

Chemical Properties

• CAS DataBase Reference: C₁₄H₁₇ClFNO₄(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₄H₁₇ClFNO₄(1629658-28-1)
• EPA Substance Registry System: C₁₄H₁₇ClFNO₄(1629658-28-1)

Safety Data

• Hazardous Substances Data: 1629658-28-1(Hazardous Substances Data)

Upstream product

• 93267-04-0 N-(tert-butoxycarbonyl)-L-3-iodoalanine methyl ester 
• 202982-67-0 1-chloro-2-fluoro-4-iodo-benzene 
• 944804-98-2 (S)-methyl 2-((tert-butoxycarbonyl)amino)-3-(4-chloro-3-fluorophenyl)propanoate 
• 5527-95-7 4-chloro-3-fluorobenzaldehyde 
• 1001179-10-7 (Z)-methyl 2-(tert-butoxycarbonyl)-3-(4-chloro-3-fluorophenyl)acrylate 
• 1001123-82-5 (R)-methyl 2-(tert-butoxycarbonylamino)-3-(4-chloro-3-fluorophenyl)propanoate 

Downstream Products

• 1001125-25-2 tert-butyl (2R)-3-(4-chloro-3-fluorophenyl)-1-(4-(5-ethyl-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-1-oxopropan-2-ylcarbamate 

Relevant articles and documents

Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions

The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS

The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Formula (I). Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS

The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula (I): Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.